When Therapeutic IgA Antibodies Might Come of Age.
Pharmacology
; 106(1-2): 9-19, 2021.
Article
in English
| MEDLINE | ID: covidwho-1066969
ABSTRACT
BACKGROUND:
Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeutic strategies.SUMMARY:
Here, we underline that IgA is more effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including rotavirus, poliovirus, influenza virus, and SARS-CoV-2. IgA could also be used to modulate excessive immune responses in inflammatory diseases. Furthermore, secretory IgA is emerging as a major regulator of gut microbiota, which impacts intestinal homeostasis and global health as well. As such, IgA could be used to promote a healthy microbiota in a therapeutic setting. Key messages IgA combines multifaceted functions that can be desirable for immunotherapy.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Immunoglobulin A
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Immunotherapy
/
Antibodies, Monoclonal
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
000510251
Similar
MEDLINE
...
LILACS
LIS